IDT breaks into generic drugs with US filing
18 November, 2013 by Dylan Bushell-EmblingPharmaceutical manufacturing company IDT Australia (ASX:IDT) has filed the first of a series of planned marketing applications for generic drugs, with a US filing for chemotherapy temozolomide.
Regeneus gets US green light for cancer vaccine
14 November, 2013 by Dylan Bushell-EmblingRegeneus (ASX:RGS) has received US regulatory approval to commercialise a cell-based canine cancer vaccine in the US, giving it an accelerated pathway to launch.
Simavita to list on Toronto exchange
14 November, 2013 by Susan WilliamsonMedical device company Simavita is planning to raise AU$15 million via an IPO, with the aim of listing on Canada’s Toronto Stock Exchange.
AusBiotech releases calendar for 2014 major events
14 November, 2013The latest calendar for AusBiotech’s line-up of major life sciences events brings you all your favourites and some new additions, amounting to a broad range of networking, learning and sponsorship opportunities. Save the dates now for 2014 …
iSonea CEO to resign in May
13 November, 2013 by Dylan Bushell-EmblingiSonea (ASX:ISN) will hunt for an international sales exec to replace its outgoing CEO, while Starpharma (ASX:SPL) has named the person slated to replace its long-serving chairman.
Medical device sector's time to shine
12 November, 2013 by Dylan Bushell-EmblingThe medical device segment was the star performer of the Australian life sciences sector during Q413, and the stage is set for further growth, PwC's latest BioForum report says.
Mesoblast MPCs may extend stroke treatment window
12 November, 2013 by Dylan Bushell-EmblingMesoblast's (ASX:MSB) detailed preclinical research suggests that its proprietary MPCs could improve recovery in ischemic stroke patients, even when injected up to seven days post stroke.
CSL named most respected life science company
12 November, 2013Biotechnology major CSL was last week named Australia's most respected 'chemical/life sciences' company, appearing for the first time in the top 10 companies in the Australian Financial Review's 'Boss' magazine annual study.
Trial confirms efficacy of Clinuvel drug in EPP
11 November, 2013 by Dylan Bushell-EmblingClinuvel (ASX:CUV) said its Scenesse drug was able to relieve symptoms and improve quality of life in patients with rare genetic disease EPP during a phase III trial.
Immuron widens scope for liver treatment
08 November, 2013 by Dylan Bushell-EmblingImmuron (ASX:IMC) has received an approval to trial its IMM-124E in ASH as well as NASH, and animal studies support its utility in treating liver fibrosis.
MTAA awards achievements in medical technology
08 November, 2013The Medical Technology Association of Australia (MTAA) last night held its annual conference dinner as part of the MedTech 2013 conference in Sydney, where the association presented two awards for achievements in medical technology.
AusBiotech signs MoU with KoreaBIO
07 November, 2013The AusBiotech 2013 national conference culminated last week in the signing of a memorandum of understanding (MoU) between AusBiotech and the Korea Biotechnology Industry Organization (KoreaBIO).
Personalised medicine
06 November, 2013 by Susan WilliamsonThe investment that has been put into personalised medicine is starting to pay off - the tailored diagnosis, prognosis, treatment and prevention of disease in an individual is beginning to be applied, as David Randerson intends to explain at the conference.
AusBiotech announces new directors at AGM
05 November, 2013AusBiotech has announced the election of two new directors to its board at its annual general meeting in Brisbane last week - Julie Phillips, CEO of BioDiem; and Dr Andrea Douglas, vice president, R&D strategy and portfolio at CSL.
Clinuvel to start new vitiligo trial
05 November, 2013 by Dylan Bushell-EmblingClinuvel (ASX:CUV) is awaiting approval to commence a new phase II trial of Scenesse in vitiligo, to help confirm the positive findings of an earlier trial.
